These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 18192943

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].
    Lièvre M.
    Rev Prat; 2001 Oct 15; 51(16):1793-9. PubMed ID: 11795124
    [Abstract] [Full Text] [Related]

  • 6. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K, Miller NH.
    J Am Acad Nurse Pract; 2009 Jan 15; 21(1):66-75. PubMed ID: 19125897
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 15; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 9. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B, Devereux RB, Kjeldsen SE, Lyle PA, Zhang Z, Edelman JM.
    Blood Press; 2007 Jul 15; 16(1):6-12. PubMed ID: 17453746
    [Abstract] [Full Text] [Related]

  • 10. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA, Epstein BJ, Roberts ME.
    J Am Acad Nurse Pract; 2008 Nov 15; 20(11):529-38. PubMed ID: 19128336
    [No Abstract] [Full Text] [Related]

  • 11. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B.
    J Hum Hypertens; 2009 Feb 15; 23(2):77-85. PubMed ID: 18685606
    [Abstract] [Full Text] [Related]

  • 12. Management of hypertension in peripheral arterial disease: does the choice of drugs matter?
    Singer DR, Kite A.
    Eur J Vasc Endovasc Surg; 2008 Jun 15; 35(6):701-8. PubMed ID: 18375152
    [Abstract] [Full Text] [Related]

  • 13. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul 15; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 14. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ.
    Prev Cardiol; 2008 Jul 15; 11(4):215-22. PubMed ID: 19476574
    [Abstract] [Full Text] [Related]

  • 15. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB.
    Postgrad Med; 2009 Mar 15; 121(2):89-101. PubMed ID: 19332966
    [Abstract] [Full Text] [Related]

  • 16. Protective effects of renin-angiotensin blockade beyond blood pressure control.
    Mancia G, Giannattasio C, Seravalle G, Quarti-Trevano F, Grassi G.
    J Hum Hypertens; 2009 Sep 15; 23(9):570-7. PubMed ID: 19190657
    [Abstract] [Full Text] [Related]

  • 17. Management of hypertension in patients with chronic kidney disease and diabetes mellitus.
    Palmer BF.
    Am J Med; 2008 Aug 15; 121(8 Suppl):S16-22. PubMed ID: 18638614
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support.
    Colvine K, Kerr AJ, McLachlan A, Gow P, Kumar S, Ly J, Wiltshire C, Robinson E, Dalbeth N.
    N Z Med J; 2008 Nov 07; 121(1285):73-81. PubMed ID: 19079439
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 07; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 20. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure.
    Fuchs FD.
    Expert Rev Cardiovasc Ther; 2004 Sep 07; 2(5):771-5. PubMed ID: 15350178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.